Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EWTX
stocks logo

EWTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.438
+4.19%
--
--
-0.450
+4.65%
--
--
-0.470
+38.24%
Estimates Revision
Stock Price
Go Up
up Image
+52.28%
In Past 3 Month
Wall Street analysts forecast EWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EWTX is 37.00 USD with a low forecast of 20.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast EWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EWTX is 37.00 USD with a low forecast of 20.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 23.710
sliders
Low
20.00
Averages
37.00
High
51.00
Current: 23.710
sliders
Low
20.00
Averages
37.00
High
51.00
JPMorgan
Tessa Romero
maintain
$33 -> $34
2025-11-14
Reason
JPMorgan
Tessa Romero
Price Target
$33 -> $34
2025-11-14
maintain
Reason
JPMorgan analyst Tessa Romero raised the firm's price target on Edgewise Therapeutics to $34 from $33 and keeps an Overweight rating on the shares. The firm updated the company's model.
JPMorgan
Overweight
maintain
$30 -> $33
2025-11-03
Reason
JPMorgan
Price Target
$30 -> $33
2025-11-03
maintain
Overweight
Reason
JPMorgan raised the firm's price target on Edgewise Therapeutics to $33 from $30 and keeps an Overweight rating on the shares. The firm upped the price target after revisiting its epidemiology and diagnosis rate assumptions for obstructive and nonobstructive hypertrophic cardiomyopathy. Diagnosis trends indicate nonobstructive hypertrophic cardiomyopathy is growing at a faster rate than obstructive and could account for up to half of the total HCM market over time, the analyst tells investors in a research note.
Goldman Sachs
Early-Stage Biotech -> Neutral
maintain
$20
2025-09-24
Reason
Goldman Sachs
Price Target
$20
2025-09-24
maintain
Early-Stage Biotech -> Neutral
Reason
Goldman Sachs assigned a Neutral rating and $20 price target to Edgewise Therapeutics after having previously covered the stock with an Early-Stage Biotech rating.
Goldman Sachs
Early-Stage Biotech -> Neutral
downgrade
$20
2025-09-24
Reason
Goldman Sachs
Price Target
$20
2025-09-24
downgrade
Early-Stage Biotech -> Neutral
Reason
Goldman Sachs assigned a Neutral rating and $20 price target to Edgewise Therapeutics after having previously covered the stock with an Early-Stage Biotech rating. While the firm sees blockbuster potential for the company's programs across multiple indications including sevasemten in Becker muscular dystrophy, where there is no currently approved FDA therapy, and Duchenne muscular dystrophy, it also sees limited opportunities for the stock to re-rate over the next 12 months given expected clinical and regulatory updates.
JPMorgan
Overweight
to
NULL
downgrade
$40 -> $30
2025-08-19
Reason
JPMorgan
Price Target
$40 -> $30
2025-08-19
downgrade
Overweight
to
NULL
Reason
JPMorgan lowered the firm's price target on Edgewise Therapeutics to $30 from $40 and keeps an Overweight rating on the shares. JPMorgan also removed the stock from its Analyst Focus List. The firm is took a more conservative approach to sevasemten in its lead neuromuscular indications post the Q2 report. However, JPMorgan's our positive fundamental view of Edgewise remains, as it sees the company's cardiovascular assets driving most value for the stock in the mid- to longer-term.
Raymond James
Martin Auster
Strong Buy
initiated
$46
2025-07-29
Reason
Raymond James
Martin Auster
Price Target
$46
2025-07-29
initiated
Strong Buy
Reason
Raymond James analyst Martin Auster initiated coverage of Edgewise Therapeutics with a Strong Buy rating and $46 price target. The firm sees a highly attractive risk/reward profile for the shares at current levels. Edgewise's Phase 2 CIRRUS-HCM Part D results in the second half of 2025 can "meaningfully de-risk" EDG-7500 in hypertrophic cardiomyopathy, the analyst tells investors in a research note. The firm sees a path forward for the drug to potentially avoid a risk evaluation and mitigation strategy.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Edgewise Therapeutics Inc (EWTX.O) is -12.76, compared to its 5-year average forward P/E of -10.72. For a more detailed relative valuation and DCF analysis to assess Edgewise Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.72
Current PE
-12.76
Overvalued PE
-3.93
Undervalued PE
-17.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.10
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.68
Undervalued EV/EBITDA
-13.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

EWTX News & Events

Events Timeline

(ET)
2025-11-10
08:06:45
Edgewise Therapeutics CFO Michael Carruthers Announces Retirement; Michael Nofi to Take Over
select
2025-11-06 (ET)
2025-11-06
08:05:21
Edgewise Therapeutics announces Q3 earnings per share of 39 cents, below consensus estimate of 40 cents.
select
2025-08-07 (ET)
2025-08-07
08:04:27
Edgewise Therapeutics reports Q2 EPS (34c), consensus (42c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-02Newsfilter
Edgewise Grants 26,250 Stock Options to New Employee Under Inducement Plan
  • Inducement Plan Launch: On November 28, 2025, Edgewise Therapeutics granted 26,250 stock options to a new non-executive employee at an exercise price of $26.04 per share, aligning with the company's 2024 Inducement Equity Incentive Plan to attract talent and enhance employee loyalty.
  • Equity Incentive Structure: The stock options vest 25% on the one-year anniversary of the employee's start date, with an additional 1/48th vesting monthly thereafter, ensuring ongoing contributions during the employee's tenure, which enhances team stability and business continuity.
  • Compliance Assurance: This stock option grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring the company's adherence to regulations in attracting and retaining key talent, thereby reducing potential legal risks.
  • Mission Reinforcement: Edgewise is dedicated to developing novel therapeutics for muscle diseases and cardiac conditions, and this incentive measure not only boosts employee morale but also drives the company's innovative capabilities in clinical trials and market outreach.
[object Object]
Preview
5.0
11-20PRnewswire
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

  • Appointment of Christopher Martin: Edgewise Therapeutics has appointed Christopher Martin, a biotechnology veteran, to its Board of Directors, recognizing his extensive experience in commercial functions and product launches.

  • Focus on Commercial Launch: Martin's expertise is expected to be crucial as Edgewise prepares for its first commercial launch in Becker muscular dystrophy and advances its cardiovascular asset to Phase 3 trials.

  • Background of Christopher Martin: Prior to joining Edgewise, Martin held significant roles at Verona Pharma, SK Life Science, and Cempra, where he successfully led marketing and launch strategies for various pharmaceutical products.

  • Edgewise Therapeutics Overview: Edgewise is a biopharmaceutical company focused on developing novel therapeutics for muscular dystrophies and cardiac conditions, with key products in various stages of clinical development.

[object Object]
Preview
9.5
11-17Yahoo Finance
Edgewise Therapeutics (EWTX) Announces Increased R&D Efforts in Q3 2025

  • Company Overview: Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a biopharmaceutical company focused on developing therapies for muscular dystrophies and serious cardiac conditions.

  • Q3 2025 Financial Results: The company reported a net loss of $40.7 million for Q3 2025, with R&D expenses increasing to $37.5 million due to ongoing clinical activities, while maintaining a cash balance of $563.3 million.

  • Clinical Advancements: Edgewise's muscular dystrophy and cardiac programs are progressing, with significant milestones expected, including the GRAND CANYON cohort readout in Q4 2026 and updates on the Phase 2 CIRRUS-HCM trial in Q4 2025.

  • Investment Perspective: While analysts recognize EWTX's potential as an investment, they suggest that certain AI stocks may offer better upside potential and lower risk.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Edgewise Therapeutics Inc (EWTX) stock price today?

The current price of EWTX is 23.71 USD — it has increased 1.67 % in the last trading day.

arrow icon

What is Edgewise Therapeutics Inc (EWTX)'s business?

Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.

arrow icon

What is the price predicton of EWTX Stock?

Wall Street analysts forecast EWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EWTX is 37.00 USD with a low forecast of 20.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Edgewise Therapeutics Inc (EWTX)'s revenue for the last quarter?

Edgewise Therapeutics Inc revenue for the last quarter amounts to -46.86M USD, increased 15.89 % YoY.

arrow icon

What is Edgewise Therapeutics Inc (EWTX)'s earnings per share (EPS) for the last quarter?

Edgewise Therapeutics Inc. EPS for the last quarter amounts to -34865000.00 USD, increased 24.99 % YoY.

arrow icon

What changes have occurred in the market's expectations for Edgewise Therapeutics Inc (EWTX)'s fundamentals?

The market is revising No Change the revenue expectations for EWTX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 52.28%.
arrow icon

How many employees does Edgewise Therapeutics Inc (EWTX). have?

Edgewise Therapeutics Inc (EWTX) has 110 emplpoyees as of December 05 2025.

arrow icon

What is Edgewise Therapeutics Inc (EWTX) market cap?

Today EWTX has the market capitalization of 2.51B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free